GSK's DREAMM 12 posts results with 36 enrolled; COSTAR Lung stays active, not recruiting

GSK had two oncology trial updates on record this period.

• DREAMM 12 (NCT04398745), a Phase 1 study of belantamab mafodotin in relapsed/refractory multiple myeloma patients with normal and impaired renal function, had results first posted on 2026-07-01. The purpose of this study is to assess the pharmacokinetics (PK), safety, and tolerability of belantamab mafodotin monotherapy in participants with RRMM, who have had at least 3 lines of prior treatment (or at least 2 lines of prior treatment if ineligible for autologous stem cell transplantation) and have either normal or impaired renal functions.¹ The trial's enrollment was 36 participants (actual).¹
• COSTAR Lung (NCT04655976), a Phase 2/3 study of cobolimab combined with dostarlimab and docetaxel versus dostarlimab plus docetaxel versus docetaxel alone, remains active but not recruiting. This is a multi-center, parallel group treatment, Phase 2/3 open label study evaluating cobolimab in combination with dostarlimab and docetaxel in participants with advanced non-small cell Lung Cancer (NSCLC) who have progressed on prior anti-PD-(L)1 therapy and chemotherapy.² The trial's enrollment was 758 participants (actual)², with primary completion listed as 2025-06-05 and study completion estimated for 2027-03-30.